SCHEMBL8189288

SCHEMBL8189288

[c]1[nH]ccc1C1CCc2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 3/20 0.49
PDPK1 O15530 1/20 0.42
ADRA2A P08913 2/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1B P35368 1/20 0.40
IDO1 P14902 2/20 0.39
SIGMAR1 Q99720 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
CYP11B2 P19099 2/20 0.37
HTR1A P08908 1/20 0.37
OPRM1 P35372 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP2D6 P10635 1/20 0.37
PRCP P42785 1/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4795332 0.72 ADRA1A (0.44) ADRA1APDPK1ADRA2AADRA1DADRA1B
SCHEMBL4278950 0.69 ADRA1A (0.51) ADRA1APDPK1ADRA2AADRA1DADRA1B
SCHEMBL1504258 0.69 ADRA1A (0.41) ADRA1APDPK1ADRA2AIDO1SIGMAR1
SCHEMBL11187934 0.69 ADRA1A (0.48) ADRA1APDPK1ADRA2AADRA1DADRA1B
SCHEMBL29390302 0.69 SIGMAR1 (0.62) ADRA1ASIGMAR1TAAR1CYP11B2CYP2D6
SCHEMBL503849 0.69 SIGMAR1 (0.62) ADRA1ASIGMAR1TAAR1CYP11B2CYP2D6
SCHEMBL28806293 0.67 ADRA1A (0.49) ADRA1APDPK1ADRA2AADRA1DADRA1B
SCHEMBL30606845 0.67 SIGMAR1 (0.60) ADRA1ASIGMAR1TAAR1CYP11B2CYP2D6
SCHEMBL14247675 0.67 ADRA1A (0.49) ADRA1APDPK1ADRA2AADRA1DADRA1B
Ammonia Solution, Strong SCHEMBL8210515 0.67 SIGMAR1 (0.60) ADRA1ASIGMAR1TAAR1CYP11B2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed